Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Background: Intracoronary imaging and physiology guidance of percutaneous coronary intervention (PCI) have shown significant improvements in clinical outcomes. However, comparable data on the use of these modalities in PCI of patients with diabetes are only sparsely available from South Asia. This study investigated the feasibility and clinical outcomes of systematic use of fractional flow reserve (FFR) and optical coherence tomography (OCT) during PCI in patients with diabetes.

Methods: The study enrolled 275 patients (≥ 18 years) from nine centers in India and one from Bangladesh between October 2021 and September 2022. Patients with stable ischemic heart disease, non-ST-elevation myocardial infarction (MI), and unstable angina were included in the study. Angiographically intermediate lesions (diameter stenosis of 40% to 80%) underwent FFR-guided PCI. Lesions with a diameter stenosis of > 80% underwent PCI without FFR evaluation. All PCI procedures were guided by OCT using the MLD-MAX algorithm.

Results: At 12 months, the target lesion failure (TLF) rate, a composite of cardiac death, nonfatal MI, and clinically driven target lesion revascularization, was 3.3%. Among the intermediate lesions, PCI was deferred by 70% after the FFR evaluation. Pre- and post-procedural OCT has led to a strategy change in 49.5% and 33.6%, respectively.

Conclusions: The study revealed a relatively lower rate of events with FFR and OCT guidance compared to historical data from angiography-guided PCI in patients with diabetes. The strategy of combined use of FFR and OCT in PCI may contribute to improved clinical outcomes in patients with diabetes.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12074682PMC
http://dx.doi.org/10.14740/cr2052DOI Listing

Publication Analysis

Top Keywords

patients diabetes
16
clinical outcomes
12
pci patients
12
pci
9
systematic fractional
8
fractional flow
8
flow reserve
8
optical coherence
8
coherence tomography
8
percutaneous coronary
8

Similar Publications

Retinol binding protein 4 (RBP4), the circulating carrier of retinol, complexes with transthyretin (TTR) and is a potential biomarker of cardiometabolic disease. However, RBP4 quantitation relies on immunoassays and Western blots without retinol and TTR measurement. A liquid chromatography-tandem mass spectrometry (LC-MS/MS) method for the simultaneous absolute quantitation of circulating RBP4 and TTR is critical to establishing their biomarker potential.

View Article and Find Full Text PDF

Introduction: Diabetes Mellitus is a chronic disease characterised by elevated plasma glucose (PG) levels. HbA1c has been widely utilized for diabetes diagnosis. However, certain conditions restrict its use.

View Article and Find Full Text PDF

BackgroundAlzheimer's disease (AD) is the most common neurodegenerative disorder. While AD diagnosis traditionally relies on clinical criteria, recent trends favor a precise biological definition. Existing biomarkers efficiently detect AD pathology but inadequately reflect the extent of cognitive impairment or disease heterogeneity.

View Article and Find Full Text PDF

BackgroundCoronavirus Disease 2019 (COVID-19) has led to dramatic changes including social distancing, closure of schools, travel bans, and issues of stay-at-home orders. The health-care field has been transformed with elective procedures and on-site visits being deferred. Telemedicine has emerged as a novel mechanism to continue to provide care.

View Article and Find Full Text PDF

Sodium-glucose co-transporter 2 inhibitors (SGLT2i) are a fairly new class of agents for diabetes that have demonstrated significant benefits in glycemic control and cardiovascular outcomes with outpatient use. The aim of this review is to provide an overview of the effect of SGLT2i use on glycemic control and clinical outcomes in the hospital setting.An electronic search of PubMed was conducted to analyze publications that assessed the inpatient use of SGLT2i and included patients with diabetes.

View Article and Find Full Text PDF